WO2000068249B1 - Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor - Google Patents
Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses thereforInfo
- Publication number
- WO2000068249B1 WO2000068249B1 PCT/US2000/012502 US0012502W WO0068249B1 WO 2000068249 B1 WO2000068249 B1 WO 2000068249B1 US 0012502 W US0012502 W US 0012502W WO 0068249 B1 WO0068249 B1 WO 0068249B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gpm
- protein
- cell
- seq
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Novel G protein modulator (GPM) polypeptides, proteins, and nucleic acid molecules are disclosed, which stimulate G protein activity in a receptor-independent manner. In addition to isolated, full-length GPM proteins, the invention further provides isolated GPM fusion proteins, antigenic peptides and anti-GPM antibodies. The invention also provides GPM nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a GPM gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
Claims
AMENDED CLAIMS
[received by the International Bureau on 17 July 2001 ( 17 07.01); original claims 13, 14, 17, 20 and 21 amended; new claims 36-39 added; remaining claims unchanged (4 pages)]
9. Antibodies that specifically bind the GPM protein of claim 6
10. The antibodies of claim 9, which are monoclonal.
11. The antibodies of claim 9, which are polyclonal .
12. A pharmaceutical composition comprising the antibodies of claim 9 and a pharmaceutically acceptable carrier.
13. A method for identifying a compound that modulates signal transduction in a cell, comprising: contacting a cell that expresses a G protein modulator (GPM) protein with a test compound; determining the effect of the test compound on the cell associated activity of the GPM protein; and identifying the test compound as a modulator of signal transduction based on the ability of the compound to modulate the cell associated activity of the GPM protein in the cell, wherein the GPM protein modulates G protein cell associated activity in a receptor-independent manner.
14. The method of claim 13, wherein the GPM protein comprises an ammo acid sequence selected from the group consisting Of SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 8.
15. The method of claim 13, wherein the cell has been engineered to express the GPM protein by introducing into the cell an expression vector encoding the GPM protein.
16. The method of claim 15, wherein the cell has further been engineered to express a G protein subunit.
17. The method of claim 16, wherein the cell is a yeast cell that has been engineered to express a mammalian or chimeric O protein subunit and the effect of the test
94
compound on the cell associated activity of the GPM protein is determined by monitoring a pheromone response pathway in the yeast cells.
18. The method of claim 17, wherein the yeast cell has been engineered to express a Gpal-G i2 chimeric G protein subunit
19. The method of claim 17, wherein the pheromone response pathway in the yeast cells is monitored by measuring the activity of a pheromone responsive promoter in the yeast cells .
20. The method of claim 13, wherein the effect of the test compound on the cell associated activity of the GPM protein is determined by monitoring the ability of the test compound to bind to the GPM protein.
21. The method of claim 13, wherein the effect of the test compound on the cell associated activity of the GPM protein is determined by monitoring the ability of the test compound to modulate the interaction of the GPM protein with a target molecule.
22. The method of claim 21, wherein the target molecule is a G protein.
23. A method for modulating a cell associated activity comprising contacting a cell with an agent which modulates GPM protein activity or GPM nucleic acid expression such that a cell associated activity is altered in the cell, relative to a cell associated activity of the cell in the absence of the agent.
95
24. The method of claim 23, wherein the cell-associated activity is a G-protein mediated activity,
25. The method of claim 23, wherein the agent stimulates GPM activity or expression.
26. The method of claim 23, wherein the agent is an active GPM protein.
27. The method of claim 23, wherein the agent is a nucleic acid encoding GPM that has been introduced into the cell.
28. The method of claim 23, wherein the agent inhibits GPM activity or expression.
29. The method of claim 23, wherein the agent is an antisense GPM nucleic acid molecule.
30. The method of claim 23, wherein the agent is an antibody that specifically binds to GPM.
31. The method of claim 23, wherein the cell is present within a subject and the agent is administered to the subject.
32. A method for treating a subject having a disorder characterized by aberrant GPM protein activity or nucleic acid expression comprising administering to the subject a GPM modulator such that treatment of the subject occurs.
33. A method for detecting the presence of GPM in a biological sample comprising contacting a biological sample with an agent capable of detecting GPM protein or RNA such that the presence of GPM is detected in the biological sample.
96
34. The method of claim 33, wherein the agent is a labeled or labelable nucleic acid probe capable of hybridizing to GPM RNA.
35. The method of claim 33, wherein the agent is a labeled or labelable antibody capable of specifically binding to GPM protei .
36. The method of claim 14, wherein the GPM protein comprises an a ino acid sequence at least 70% homologous to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 6, or SEQ ID NO : 8.
37. The method of claim 14, wherein the GPM protein comprises an amino acid sequence at least 80% homologous to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 6, or SEQ ID NO : 8.
38. The method of claim 13, wherein the GPM protein comprises an amino acid sequence of SEQ ID NO: 3.
39. The method of claim 14, wherein the GPM protein comprises at least one G protein regulatory motif having an amino acid sequence at least 70% homologous to SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00930459A EP1179006A4 (en) | 1999-05-07 | 2000-05-05 | NEW PROTEIN G PROTEIN MODULATOR (GPM) PROTEINS, NUCLEIC ACID MOLECULES, AND USES THEREOF |
| AU48276/00A AU4827600A (en) | 1999-05-07 | 2000-05-05 | Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30710599A | 1999-05-07 | 1999-05-07 | |
| US09/307,105 | 1999-05-07 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2000068249A2 WO2000068249A2 (en) | 2000-11-16 |
| WO2000068249A3 WO2000068249A3 (en) | 2001-10-25 |
| WO2000068249B1 true WO2000068249B1 (en) | 2002-01-17 |
Family
ID=23188261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/012502 Ceased WO2000068249A2 (en) | 1999-05-07 | 2000-05-05 | Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1179006A4 (en) |
| AU (1) | AU4827600A (en) |
| WO (1) | WO2000068249A2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001519157A (en) * | 1997-10-07 | 2001-10-23 | ケイダス ファーマスーティカル コーポレイション | Yeast cells expressing modified G protein and methods of using them |
| AU3977699A (en) * | 1998-05-08 | 1999-11-29 | Cadus Pharmaceutical Corporation | Ags proteins and nucleic acid molecules and uses therefor |
| AUPQ223999A0 (en) * | 1999-08-16 | 1999-09-09 | University Of Sydney, The | Intracellular feedback controls in the diagnosis and treatment of human disease |
-
2000
- 2000-05-05 EP EP00930459A patent/EP1179006A4/en not_active Withdrawn
- 2000-05-05 WO PCT/US2000/012502 patent/WO2000068249A2/en not_active Ceased
- 2000-05-05 AU AU48276/00A patent/AU4827600A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000068249A2 (en) | 2000-11-16 |
| AU4827600A (en) | 2000-11-21 |
| EP1179006A2 (en) | 2002-02-13 |
| EP1179006A4 (en) | 2003-03-19 |
| WO2000068249A3 (en) | 2001-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ringwald et al. | The structure of cell adhesion molecule uvomorulin. Insights into the molecular mechanism of Ca2+‐dependent cell adhesion. | |
| US9005911B2 (en) | Methods for identifying inhibitors of botulinum neurotoxins | |
| CA2413857A1 (en) | Pd-l2 molecules: pd-1 ligands and uses therefor | |
| AU743490B2 (en) | NTN-2 member of TNF ligand family | |
| KR100210183B1 (en) | Cell-free receptor binding assays the production and use thereof | |
| Carson | Receptor for the group B coxsackieviruses and adenoviruses: CAR | |
| CA2353086A1 (en) | Pgc-1, a novel brown fat ppar.gamma. coactivator | |
| CA2383424A1 (en) | Novel b7-4 molecules and uses therefor | |
| CA2290944A1 (en) | Pgc-1, a novel brown fat ppar.gamma. coactivator | |
| CA2309903A1 (en) | Nucleic acid sequences encoding capsaicin receptor | |
| SZAKÁCS et al. | Role of glycine-534 and glycine-1179 of human multidrug resistance protein (MDR1) in drug-mediated control of ATP hydrolysis | |
| WO1999007738A2 (en) | Human orphan receptor ntr-1 | |
| JPH111498A (en) | Myc-binding zinc finger protein, method for producing the same and use thereof | |
| CN113599512B (en) | Immune composition | |
| Almenoff et al. | Induction of heat-stable enterotoxin receptor activity by a human Alu repeat | |
| JP4604184B2 (en) | Novel sugar chain recognition protein and its gene | |
| US20160333386A1 (en) | Use of peptidylglycine alpha-amidating monooxigenase (pam) for c-terminal amidation | |
| US6420120B1 (en) | Use of a polypeptide as cell receptor for adenoviruses | |
| WO2000068249B1 (en) | Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor | |
| US20020127624A1 (en) | INGAP displacement assays | |
| KR940007181A (en) | Isolation, Characterization and Protein Sequencing and Cloning of Genes Encoding Growth Hormone Release Hormone Receptors | |
| JP4423394B2 (en) | Novel sugar chain recognition protein and its gene | |
| WO2004007551A1 (en) | Splice variant cannabinoid receptor (cb1b) | |
| US5196526A (en) | CDNA clone for T-cell suppressor inducer factor | |
| EA200300420A1 (en) | Isolated nucleic acid molecules, isolated polypeptides AND METHOD FOR PRODUCTION THEREOF, METHOD FOR DETECTING THEM present in the sample (VARIANTS) host cell (VARIANTS) antibody kit (OPTIONS), a method of modulating activity of a polypeptide, IDENTIFICATION METHOD (VARIANTS) AND APPLICATION OF COMPOUNDS METHOD OF IDENTIFICATION OF THE SUBJECT (OPTIONS) AND METHOD OF TREATING THE SUBJECT WITH DAMAGE ASSOCIATED WITH POTASSIUM CHANNELS (OPTIONS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000930459 Country of ref document: EP |
|
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| B | Later publication of amended claims | ||
| WWP | Wipo information: published in national office |
Ref document number: 2000930459 Country of ref document: EP |
|
| NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000930459 Country of ref document: EP |